Aimmune Therapeutics (AIMT) Lifted to Strong-Buy at ValuEngine

Aimmune Therapeutics (NASDAQ:AIMT) was upgraded by stock analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Thursday.

AIMT has been the topic of a number of other reports. BidaskClub downgraded shares of Aimmune Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 11th. Roth Capital set a $80.00 price objective on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research report on Tuesday, October 9th. Wedbush started coverage on shares of Aimmune Therapeutics in a research report on Wednesday, October 17th. They set a “buy” rating and a $72.00 price objective on the stock. Stifel Nicolaus started coverage on shares of Aimmune Therapeutics in a research report on Thursday, September 13th. They set a “hold” rating and a $33.00 price objective on the stock. Finally, Credit Suisse Group set a $40.00 price objective on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research report on Monday, August 13th. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Aimmune Therapeutics has a consensus rating of “Buy” and a consensus target price of $50.70.

Aimmune Therapeutics stock traded up $4.33 during mid-day trading on Thursday, reaching $30.91. 1,231,737 shares of the company traded hands, compared to its average volume of 627,066. The company has a market cap of $1.53 billion, a P/E ratio of -11.84 and a beta of -0.27. Aimmune Therapeutics has a 52-week low of $24.56 and a 52-week high of $42.00.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.86) by ($0.05). As a group, sell-side analysts expect that Aimmune Therapeutics will post -3.64 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in AIMT. Wells Fargo & Company MN grew its position in shares of Aimmune Therapeutics by 7.6% in the 1st quarter. Wells Fargo & Company MN now owns 67,954 shares of the biotechnology company’s stock worth $2,163,000 after buying an additional 4,796 shares during the period. California Public Employees Retirement System purchased a new stake in shares of Aimmune Therapeutics in the 1st quarter worth about $1,238,000. Jane Street Group LLC purchased a new stake in shares of Aimmune Therapeutics in the 1st quarter worth about $533,000. Legal & General Group Plc grew its position in shares of Aimmune Therapeutics by 55.2% in the 1st quarter. Legal & General Group Plc now owns 14,102 shares of the biotechnology company’s stock worth $449,000 after buying an additional 5,015 shares during the period. Finally, Royal Bank of Canada grew its position in shares of Aimmune Therapeutics by 4,412.4% in the 1st quarter. Royal Bank of Canada now owns 17,463 shares of the biotechnology company’s stock worth $555,000 after buying an additional 17,076 shares during the period. 78.01% of the stock is currently owned by hedge funds and other institutional investors.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Featured Story: How Do You Calculate Return on Investment (ROI)?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply